EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review

Gonzalo Mariscal, Jorge H Nuñez, Sanjay Bhatia, Carlos Barrios, Pedro Domenech-Fernández

Monoclonal Antibodies in Immunodiagnosis & Immunotherapy · 01.04.2020 · 39 (2) · 29-36

DOI: 10.1089/mab.2019.0049 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, online erschienen am 09.04.2020. Verfasst von Gonzalo Mariscal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research on Musculoskeletal Disorders, Valencia Catholic University, Valencia, Spain. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sclerostin is a protein synthesized mainly by osteocytes whose function is to inhibit bone formation. A recent monoclonal antibody, Romosozumab, is able to block sclerostin. The aim of this meta-analysis is to compare the safety of Romosozumab with placebo and alendronate. Five randomized controlled trials that described the safety of Romosozumab in healthy men and postmenopausal women were analyzed. The measures to be compared were the number of adverse events and the number of serious adverse events. Specific results included injection site reaction, arthralgia, nasopharyngitis, and back pain. A total of 11,741 patients were included in this meta-analysis, in three different groups: Romosozumab, alendronate, and placebo. Significant differences were seen between the groups with regard to injection site reaction: 5.88% in the Romosozumab group versus 3.62% in the placebo group (Mantel–Haenszel [M-H] 1.54, confidence interval [95% CI] 1.22–1.96; p < 0.001) and 2.62% in the alendronate group (M-H 1.8, 95% CI 1.32–2.60; p < 0.001). In addition, patients treated with Romosozumab had significantly fewer total adverse events than the alendronate group (M-H 0.85, 95% CI 0.74–0.98; p < 0.05). In conclusion, Romosozumab may have lower adverse effects compared to alendronate and comparable to a placebo, except injection site reactions. Injection site reactions were more with romosozumab compared to alendronate and compared to the placebo as well. Romosozumab appears to have a similar safety profile to bisphosphonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalFemaleHumansMaleOsteoporosisOsteoporosis, PostmenopausalPostmenopause

Stichwörter der Autor:innen

Romosozumabmeta-analysisosteoporosisrandomized controlled trialsafety

Substanzen

Antibodies, Monoclonalromosozumab

Autor:innen und Institutionen

  • Institute for Research on Musculoskeletal Disorders, Valencia Catholic University, Valencia, Spain.
  • Department of Traumatology and Orthopedic Surgery, Hospital Sant Joan de Deu, Esplugues de Llobregat, Spain.
  • Spine Unit, Department of Traumatology and Orthopedic Surgery, University Hospital of Mutua Terrassa, Terrassa, Spain.
  • Department of Neurosurgery, School of Medicine, West Virginia University, Morgantown, West Virginia.
  • Department of Traumatology and Orthopedic Surgery, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Zitieren

APA

Mariscal, G., Nuñez, J. H., Bhatia, S., Barrios, C., & Domenech-Fernández, P. (2020). Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 39(2), 29-36. https://doi.org/10.1089/mab.2019.0049

Vancouver

Mariscal G, Nuñez JH, Bhatia S, Barrios C, Domenech-Fernández P. Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. 2020;39(2):29-36. doi:10.1089/mab.2019.0049

BibTeX
@article{Mariscal2020,
  author = {Mariscal, Gonzalo and Nuñez, Jorge H and Bhatia, Sanjay and Barrios, Carlos and Domenech-Fernández, Pedro},
  title = {Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review},
  journal = {Monoclonal Antibodies in Immunodiagnosis & Immunotherapy},
  year = {2020},
  volume = {39},
  number = {2},
  pages = {29--36},
  doi = {10.1089/mab.2019.0049}
}
Kostenlos starten →